DOP2017000287A - Analogos glp-1 lipidados resistentes a proteasa - Google Patents
Analogos glp-1 lipidados resistentes a proteasaInfo
- Publication number
- DOP2017000287A DOP2017000287A DO2017000287A DO2017000287A DOP2017000287A DO P2017000287 A DOP2017000287 A DO P2017000287A DO 2017000287 A DO2017000287 A DO 2017000287A DO 2017000287 A DO2017000287 A DO 2017000287A DO P2017000287 A DOP2017000287 A DO P2017000287A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- resistant
- peptides
- proteasa
- lipides
- glp
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 108091005804 Peptidases Proteins 0.000 abstract 3
- 239000004365 Protease Substances 0.000 abstract 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000029226 lipidation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173631P | 2015-06-10 | 2015-06-10 | |
| US201662343390P | 2016-05-31 | 2016-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2017000287A true DOP2017000287A (es) | 2018-04-15 |
Family
ID=56235790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2017000287A DOP2017000287A (es) | 2015-06-10 | 2017-12-07 | Analogos glp-1 lipidados resistentes a proteasa |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10414811B2 (enExample) |
| EP (2) | EP3865504A1 (enExample) |
| JP (1) | JP6811190B2 (enExample) |
| KR (1) | KR20180016441A (enExample) |
| CN (1) | CN108271373B (enExample) |
| AU (2) | AU2016277449B2 (enExample) |
| CA (1) | CA2988841C (enExample) |
| CL (1) | CL2017003144A1 (enExample) |
| CO (1) | CO2017012675A2 (enExample) |
| CR (1) | CR20170559A (enExample) |
| DO (1) | DOP2017000287A (enExample) |
| EA (1) | EA036415B1 (enExample) |
| ES (1) | ES2849950T3 (enExample) |
| IL (1) | IL255978B (enExample) |
| MX (1) | MX389407B (enExample) |
| MY (1) | MY185816A (enExample) |
| NI (1) | NI201700156A (enExample) |
| NZ (1) | NZ738909A (enExample) |
| PE (1) | PE20180659A1 (enExample) |
| PH (1) | PH12017502259A1 (enExample) |
| SG (1) | SG10201911837SA (enExample) |
| SV (1) | SV2017005585A (enExample) |
| TN (1) | TN2017000519A1 (enExample) |
| TW (1) | TWI726889B (enExample) |
| WO (1) | WO2016198544A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017277594A1 (en) * | 2016-06-09 | 2019-02-07 | Medimmune Limited | Protease-resistant mono-lipidated peptides |
| CN111655338A (zh) * | 2017-10-31 | 2020-09-11 | 免疫医疗有限公司 | Glp-1肽类似物的口服递送 |
| UA128210C2 (uk) | 2018-04-05 | 2024-05-08 | Сан Фармасьютікал Індастріз Лімітед | Аналог glp-1 |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| IL311411A (en) | 2021-09-15 | 2024-05-01 | Viking Therapeutics Inc | Preparations and methods for the treatment of metabolic and liver disorders |
| TW202346323A (zh) * | 2022-02-07 | 2023-12-01 | 英商梅迪繆思有限公司 | 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| JP2006501820A (ja) | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法 |
| CN101010339B (zh) * | 2004-07-02 | 2011-11-09 | 布里斯托尔-迈尔斯斯奎布公司 | 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途 |
| KR20080052649A (ko) * | 2005-09-08 | 2008-06-11 | 트러스티즈 오브 터프츠 칼리지 | 안정화된 ｇｌｐ―1 유사체 |
| EP1854455B1 (en) * | 2006-05-10 | 2009-10-07 | Biocompatibles UK Limited | Spherical microcapsules comprising GLP-1 peptides, their production and use |
| WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| EP2057189B1 (en) | 2006-08-25 | 2013-03-06 | Novo Nordisk A/S | Acylated exendin-4 compounds |
| JP5351889B2 (ja) | 2007-06-21 | 2013-11-27 | テクニシェ ユニバーシタット ミュンヘン | インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質 |
| KR101277560B1 (ko) | 2007-12-11 | 2013-06-25 | 카딜라 핼쓰캐어 리미티드 | 글루카곤 안타고니스트 활성 및 ｇｌｐ-1 아고니스트 활성의 펩티드 유사체 |
| WO2010063818A2 (en) * | 2008-12-05 | 2010-06-10 | Glaxo Group Limited | Methods for selecting protease resistant polypeptides |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| US20120264685A1 (en) | 2009-10-22 | 2012-10-18 | Rajesh Bahekar | Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist |
| CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| US20130143800A1 (en) | 2011-11-07 | 2013-06-06 | Research Development Foundation | Combination therapies to treat diabetes |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| EP3459598A1 (en) | 2012-12-06 | 2019-03-27 | Stealth Peptides International, Inc. | Combinations of peptide therapeutics and methods for using same |
| AU2014230472A1 (en) * | 2013-03-14 | 2015-10-01 | Medimmune Limited | Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity |
| KR20160098406A (ko) | 2013-12-13 | 2016-08-18 | 메디뮨 리미티드 | 프로테아제 내성 펩티드 |
-
2016
- 2016-06-08 TW TW105118294A patent/TWI726889B/zh not_active IP Right Cessation
- 2016-06-09 NZ NZ738909A patent/NZ738909A/en not_active IP Right Cessation
- 2016-06-09 EA EA201792640A patent/EA036415B1/ru not_active IP Right Cessation
- 2016-06-09 EP EP20202888.2A patent/EP3865504A1/en not_active Withdrawn
- 2016-06-09 TN TNP/2017/000519A patent/TN2017000519A1/en unknown
- 2016-06-09 CN CN201680033320.4A patent/CN108271373B/zh active Active
- 2016-06-09 PE PE2017002540A patent/PE20180659A1/es unknown
- 2016-06-09 CA CA2988841A patent/CA2988841C/en active Active
- 2016-06-09 ES ES16732248T patent/ES2849950T3/es active Active
- 2016-06-09 KR KR1020177037653A patent/KR20180016441A/ko not_active Ceased
- 2016-06-09 CR CR20170559A patent/CR20170559A/es unknown
- 2016-06-09 MX MX2017015482A patent/MX389407B/es unknown
- 2016-06-09 US US15/579,774 patent/US10414811B2/en active Active
- 2016-06-09 WO PCT/EP2016/063206 patent/WO2016198544A1/en not_active Ceased
- 2016-06-09 EP EP16732248.6A patent/EP3307769B1/en active Active
- 2016-06-09 MY MYPI2017704708A patent/MY185816A/en unknown
- 2016-06-09 AU AU2016277449A patent/AU2016277449B2/en not_active Ceased
- 2016-06-09 SG SG10201911837SA patent/SG10201911837SA/en unknown
- 2016-06-09 JP JP2017563292A patent/JP6811190B2/ja active Active
-
2017
- 2017-11-28 IL IL255978A patent/IL255978B/en active IP Right Grant
- 2017-12-07 DO DO2017000287A patent/DOP2017000287A/es unknown
- 2017-12-07 CL CL2017003144A patent/CL2017003144A1/es unknown
- 2017-12-08 SV SV2017005585A patent/SV2017005585A/es unknown
- 2017-12-11 CO CONC2017/0012675A patent/CO2017012675A2/es unknown
- 2017-12-11 NI NI201700156A patent/NI201700156A/es unknown
- 2017-12-11 PH PH12017502259A patent/PH12017502259A1/en unknown
-
2019
- 2019-07-25 US US16/521,662 patent/US20200079833A1/en not_active Abandoned
- 2019-09-13 AU AU2019229424A patent/AU2019229424A1/en not_active Abandoned
-
2021
- 2021-02-08 US US17/169,833 patent/US20210221866A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| CO2017012675A2 (es) | Péptidos lipidados resistentes a proteasas | |
| CY1120730T1 (el) | Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1 | |
| MX2016013034A (es) | Composicion detergente. | |
| MX369041B (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| CO2017005995A2 (es) | Composiciones para el cuidado bucal y métodos de uso | |
| CL2017000053A1 (es) | Anticuerpos de unión a protofibrillas aß | |
| CO2018012258A2 (es) | Compuestos de mic-1 y usos de estos | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| MX2017002803A (es) | Coronavirus bovino atenuado y vacunas relacionadas. | |
| BR112016013157A2 (pt) | peptídeos resistentes à protease | |
| PH12017500304A1 (en) | Vaccine compositions against dengue virus diseases | |
| EP3223809A4 (en) | Amino acid compositions for the treatment of symptoms of disease | |
| BR112018072968A2 (pt) | peptídeos monolipidados resistentes às proteases | |
| MX2017000467A (es) | Nuevo proceso para la purificacion de rhu-gcsf. | |
| DOP2020000082A (es) | Administración oral de análogos del péptido glp-1 | |
| MX381944B (es) | Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos. | |
| MX2017004312A (es) | Composicion farmaceutica oral de baja dosis de isotretinoina. | |
| DOP2017000014A (es) | Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo | |
| MX386458B (es) | Composiciones de péptidos t inmuno-terapéuticas para usarse en el tratamiento de metástasis cerebrales. | |
| MA40027A (fr) | Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique | |
| GT201600190A (es) | Compuestos químicos | |
| CR20180110A (es) | Libobactina para uso en el tratamiento de la mastitis bovina |